GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AB Science (XPAR:AB) » Definitions » Research & Development

AB Science (XPAR:AB) Research & Development : €10.48 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is AB Science Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. AB Science's Research & Development for the six months ended in Dec. 2023 was €3.26 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was €10.48 Mil.

AB Science Research & Development Historical Data

The historical data trend for AB Science's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AB Science Research & Development Chart

AB Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.58 12.84 11.23 13.35 10.48

AB Science Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.93 8.10 5.25 7.21 3.26

AB Science Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €10.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AB Science  (XPAR:AB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

AB Science Research & Development Related Terms

Thank you for viewing the detailed overview of AB Science's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

AB Science (XPAR:AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AB Science (XPAR:AB) » Definitions » Research & Development
Comparable Companies
XPAR:MLCOT XPAR:ALRPD XPAR:EAPI ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NSE:DIVISLAB BOM:500124 VTRS NBIX SZSE:000963 SHSE:600085 XPAR:IPN
Traded in Other Exchanges
ABSCF:USA
Address
3, Avenue George V, Paris, FRA, 75008
Website
https://www.ab-science.com
AB Science is a France-based pharmaceutical company specialized in the research, discovery, development, and marketing of protein kinase inhibitors. It is engaged in targeted therapies through tyrosine kinase inhibitors for treating diseases with high medical factor in the field of cancer, chronic inflammatory diseases, neurological degenerative disorders and central nervous systems diseases in both human and veterinary medicine.